Please try another search
Vivani Medical, Inc., a preclinical stage biopharmaceutical company, engages in the development of miniaturized and subdermal implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates in the treatment of chronic disease, medication non-adherence. Its pipeline includes NPM-115, a high-dose exenatide implant candidate is in preclinical stage development for the treatment of chronic weight management in patients with obesity or overweight; NPM-119, an exenatide implant candidate is in preclinical stage development for the treatment of patients with type 2 diabetes; NPM-139, a miniature, subdermal GLP-1 implant in development for chronic weight management; and OKV-119, an exenatide implant is under development for metabolic diseases in cats including for the treatment of obesity and diabetes. The company is headquartered in Alameda, California.
Name | Age | Since | Title |
---|---|---|---|
Aaron Mendelsohn | 72 | 2022 | Director |
Dean W. Baker | 80 | 2022 | Independent Director |
Adam Mendelsohn | 42 | 2022 | Co-Founder, CEO & Director |
Gregg G. Williams | 65 | 2022 | Independent Chairman of the Board |
Alexandra L.P. Larson | 43 | 2022 | Independent Director |
Jerry A. Hausman | - | - | Advisor |
Gary T. Elliott | - | - | Advisor |
Orville G. Kolterman | 76 | - | Advisor |
Daniel Mark Bradbury | 63 | 2024 | Director & Advisor |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review